Seeing Is Believing
Currently out of the existing stock ratings of Robert Leboyer, 4 are a BUY (100%).
Analyst Robert Leboyer, currently employed at NOBLE CAPITAL, carries an average stock price target met ratio of 100% that have a potential upside of 76.51% achieved within 462 days.
Robert Leboyer’s has documented 7 price targets and ratings displayed on 2 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on TNXP, Tonix Pharmaceuticals Holding Corp at 24-May-2022.
Analyst best performing recommendations are on TNXP (TONIX PHARMACEUTICALS HOLDING CORP).
The best stock recommendation documented was for TNXP (TONIX PHARMACEUTICALS HOLDING CORP) at 5/24/2022. The price target of $10 was fulfilled within 37 days with a profit of $3.31 (24.87%) receiving and performance score of 6.72.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Hold
1 years 10 months 2 days ago
(16-Feb-2023)
0/1 (0%)
$242.25 (224.83%)
Hold
$6
$5.15 (605.88%)
2 years 3 days ago
(15-Dec-2022)
1/1 (100%)
$-4.98 (-45.36%)
1
Buy
$5
$4.11 (461.80%)
2 years 1 months 16 days ago
(02-Nov-2022)
0/1 (0%)
$3.97 (385.44%)
Buy
$7
$-0.86 (-10.94%)
$12
2 years 1 months 16 days ago
(02-Nov-2022)
2/2 (100%)
$-25.13 (-72.62%)
132
Buy
2 years 4 months 15 days ago
(03-Aug-2022)
2/2 (100%)
$-67.63 (-75.69%)
945
What Year was the first public recommendation made by Robert Leboyer?